Lotemax
(Loteprednol Etabonate)ApprovedSmall molecule
Loteprednol etabonate is a steroid eye drop used to reduce inflammation and discomfort in the eyes caused by conditions like allergies, infections, or after eye surgery.[2] Lotemax is currently approved and in use across 10 indications[4].[1]
Lotemax is one of 181 small molecule programs targeting Ocular pain. It is currently in Approved.
10
Indications
23
Total Trials
0
Active Trials
180
Competitors
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
237 competitors in Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Lotemax
BBausch & Lomb Incorporated
Approved
Lucentis
RochePhase 3
Eylea
RegeneronPhase 3
Vabysmo
RochePhase 3
Beovu
NovartisPhase 3
Macugen
PfizerPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Retaane
AAlcon Research
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Forzinity
SStealth BioTherapeutics Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cataract7 trials
Show 4 more trials
Systemic2 trials
Dexamethasone2 trials
Safety and Efficacy2 trials
8 more indications
Allergic Conjunctivitis1 trial
Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
Completed·SSouthern California College of Optometry at Marshall B. Ketchum University·Phase 4·NCT01443442·23 enrolled
Randomized1 trial
Conjunctivitis1 trial
MPA1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lotemax drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Loteprednol Etabonate. EMBL-EBI & Wellcome Sanger Institute.
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Glucocorticoid Receptor Agonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- BBausch & Lomb Incorporated